RxDoctor Payments Data

Steven Forman, MD

Cardiovascular Disease · Los Alamitos, CANPI 1023059763

Payments from drug & device makers

$99,735in general payments, 2019–2025

Across 393 payments — averaging $253.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$30K
  • Cvrx, Inc.$22K
  • Boehringer Ingelheim$13K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$10K
  • AstraZeneca$9K
  • Medtronic$8K
  • plus $8K from 41 others

What the payments were for

  • Speaking & faculty fees$7,65050%
  • Food & beverage$7,65350%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,735 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$635,730
Medicare patients
1,448
Services billed
5,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis14$308,169
EliquisApixaban258$249,496
XareltoRivaroxaban118$123,566
EntrestoSacubitril/Valsartan66$88,832
FarxigaDapagliflozin Propanediol52$43,795
JardianceEmpagliflozin29$32,115
BrilintaTicagrelor20$24,430
Repatha SureclickEvolocumab18$18,507
Metoprolol Succinate305$4,822
Atorvastatin Calcium328$3,956
Flecainide Acetate49$3,414
Dabigatran EtexilateDabigatran Etexilate Mesylate15$3,026
Carvedilol196$1,951
Rosuvastatin Calcium113$1,803
Losartan Potassium154$1,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$384$557,664272 claims
Johnson & JohnsonXarelto$597$123,566118 claims
NovartisEntresto$1,087$88,83266 claims
AstraZenecaFarxiga, Brilinta$8,614$68,22672 claims
Boehringer IngelheimJardiance$12,596$32,11529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →